AR039663A1 - Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b - Google Patents
Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2bInfo
- Publication number
- AR039663A1 AR039663A1 ARP030101424A ARP030101424A AR039663A1 AR 039663 A1 AR039663 A1 AR 039663A1 AR P030101424 A ARP030101424 A AR P030101424A AR P030101424 A ARP030101424 A AR P030101424A AR 039663 A1 AR039663 A1 AR 039663A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- dihydroquinolin
- receptor antagonists
- hydroxy
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37593902P | 2002-04-26 | 2002-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039663A1 true AR039663A1 (es) | 2005-03-02 |
Family
ID=29270728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101424A AR039663A1 (es) | 2002-04-26 | 2003-04-24 | Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6713490B2 (https=) |
| EP (1) | EP1499606B8 (https=) |
| JP (1) | JP2005524696A (https=) |
| AR (1) | AR039663A1 (https=) |
| AT (1) | ATE325117T1 (https=) |
| AU (1) | AU2003219398A1 (https=) |
| BR (1) | BR0309778A (https=) |
| CA (1) | CA2483636A1 (https=) |
| DE (1) | DE60305026T2 (https=) |
| ES (1) | ES2258716T3 (https=) |
| MX (1) | MXPA04010549A (https=) |
| PA (1) | PA8572601A1 (https=) |
| TW (1) | TW200406402A (https=) |
| UY (1) | UY27776A1 (https=) |
| WO (1) | WO2003091241A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL189872B1 (pl) | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
| WO2005035523A1 (en) * | 2003-10-08 | 2005-04-21 | Pfizer Japan Inc. | Fused lactam compounds |
| ES2246687B2 (es) * | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales. |
| EP1736474A4 (en) * | 2004-04-07 | 2010-04-21 | Kyowa Hakko Kirin Co Ltd | piperidine |
| HU226977B1 (en) * | 2004-07-29 | 2010-04-28 | Richter Gedeon Nyrt | Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them |
| WO2008027557A2 (en) * | 2006-08-31 | 2008-03-06 | Spherics, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| US8008253B2 (en) | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| WO2010036937A1 (en) | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
| WO2010113109A1 (en) * | 2009-03-31 | 2010-10-07 | Link Research & Grants Corporation | Treatment of tinnitus and associated auditory dysfunctions |
| WO2011145062A1 (en) | 2010-05-21 | 2011-11-24 | Link Research & Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
| US20130230586A1 (en) | 2010-10-02 | 2013-09-05 | Link Research & Grants Corporation | Treatment of Tinnitus and Related Auditory Dysfunctions |
| KR20140146217A (ko) | 2012-04-20 | 2014-12-24 | 유씨비 파마, 에스.에이. | 파킨슨병을 치료하는 방법 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902695A (en) | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| WO1991017156A1 (en) | 1990-05-10 | 1991-11-14 | Pfizer Inc | Neuroprotective indolone and related derivatives |
| DK0666854T3 (da) | 1992-10-30 | 1997-04-28 | Pfizer | Neurobeskyttende 3,4-dihydro-2(1H)-quinolon forbindelser |
| PE20020291A1 (es) | 2000-08-21 | 2002-04-17 | Hoffmann La Roche | Profarmacos para ligandos del receptor nmda |
-
2003
- 2003-04-14 US US10/413,029 patent/US6713490B2/en not_active Expired - Fee Related
- 2003-04-15 AT AT03715209T patent/ATE325117T1/de not_active IP Right Cessation
- 2003-04-15 EP EP03715209A patent/EP1499606B8/en not_active Expired - Lifetime
- 2003-04-15 CA CA002483636A patent/CA2483636A1/en not_active Abandoned
- 2003-04-15 MX MXPA04010549A patent/MXPA04010549A/es not_active Application Discontinuation
- 2003-04-15 DE DE60305026T patent/DE60305026T2/de not_active Expired - Fee Related
- 2003-04-15 JP JP2003587800A patent/JP2005524696A/ja not_active Withdrawn
- 2003-04-15 AU AU2003219398A patent/AU2003219398A1/en not_active Abandoned
- 2003-04-15 ES ES03715209T patent/ES2258716T3/es not_active Expired - Lifetime
- 2003-04-15 WO PCT/IB2003/001556 patent/WO2003091241A1/en not_active Ceased
- 2003-04-15 BR BR0309778-1A patent/BR0309778A/pt not_active IP Right Cessation
- 2003-04-24 UY UY27776A patent/UY27776A1/es not_active Application Discontinuation
- 2003-04-24 AR ARP030101424A patent/AR039663A1/es unknown
- 2003-04-25 TW TW092109786A patent/TW200406402A/zh unknown
- 2003-04-25 PA PA20038572601A patent/PA8572601A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003091241A1 (en) | 2003-11-06 |
| US6713490B2 (en) | 2004-03-30 |
| JP2005524696A (ja) | 2005-08-18 |
| PA8572601A1 (es) | 2004-12-16 |
| EP1499606A1 (en) | 2005-01-26 |
| TW200406402A (en) | 2004-05-01 |
| CA2483636A1 (en) | 2003-11-06 |
| ATE325117T1 (de) | 2006-06-15 |
| DE60305026T2 (de) | 2006-10-12 |
| BR0309778A (pt) | 2005-03-08 |
| EP1499606B8 (en) | 2006-08-30 |
| DE60305026D1 (de) | 2006-06-08 |
| ES2258716T3 (es) | 2006-09-01 |
| UY27776A1 (es) | 2003-11-28 |
| AU2003219398A1 (en) | 2003-11-10 |
| US20030216430A1 (en) | 2003-11-20 |
| MXPA04010549A (es) | 2005-02-17 |
| EP1499606B1 (en) | 2006-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039663A1 (es) | Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b | |
| DE69925730T2 (de) | 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten | |
| AR049540A1 (es) | Derivados de quinazolindiona como inhibidores del parp; metodos para su preparacion; composiciones farmaceuticas que los contienen como ingrediente activo y su uso en medicamentos para el tratamiento o prevencion del cancer. | |
| EP0617968B1 (en) | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | |
| WO2009050242A3 (de) | Heterocyclus-substituierte piperazino-dihydrothienopyrimidine | |
| WO2004014850A3 (en) | Substituted aminopyrimidines as neurokinin antagonists | |
| CL2011001263A1 (es) | Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma. | |
| KR20150114536A (ko) | 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드 | |
| HRP20050876A2 (en) | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | |
| IL178747A (en) | 3 - (4-amino-1-oxo-1, 3-dihydro-isoindole-2-yl) -pipridine-6,2-discussion or acceptable pharmaceutical salt, solvate or steroid isomer for use in the treatment of non-Hodgkin's lymphoma, also optional Combined with other therapeutic factors | |
| IN2012DN02968A (https=) | ||
| DE602004028150D1 (de) | Aminopyrazolderivate als gsk-3-inhibitoren | |
| AR066701A1 (es) | 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia | |
| MA32686B1 (fr) | Composés, compositions et procédés pour le traitement de maladies de la b-amyloïde et de synucléinopathies | |
| PE20221020A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1 | |
| BR0215801A (pt) | Derivados de 3,6-dissubstituìdos azabiciclo [3.1.0] hexano úteis como antagonistas de receptores muscarìnicos | |
| NZ598331A (en) | Therapeutic aryl-amido-aryl compounds and their use | |
| JOP20250025A1 (ar) | صور بلورية وأملاح من ناهض مستقبل مسكاريني | |
| DE602004016850D1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| DE60213629D1 (de) | Piperidinverbindungen als muscarinantagonisten | |
| WO2006113471A3 (en) | N-alkyl-azacycloalkyl nmda/nr2b antagonists | |
| EA200801184A1 (ru) | Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2 | |
| CL2009000491A1 (es) | Compuestos derivados de 3-(4-(2-oxoindol)-piperidin)-pirrolidinas y 3-(4-benzo[b]imidazol)-piperidin)-pirrolidinas sustituidas proceso de preparacion; composicion farmaceutica; compuestos intermediarios; utiles en el tratamiento de la terapia del dolor, de enfermedades tales como alzheimer, ansiedad, depresion y glaucoma. | |
| MX2010004686A (es) | Derivados heterociclicos. | |
| JPH06500099A (ja) | Ｃｎｓ疾病の処置におけるヘテロ環状アミノ―アルコール化合物の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |